All In Biotech

Drug Trial Radar · NCT01197755

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

(OSKIRA-3): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With Inadequate Response to a TNF-alpha Antagonist

Last checked: Nov 20, 2026Latest source record: Apr 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 323 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

323

Actual

Start

Sep 2010

Primary completion

Feb 2013

Study completion Feb 2013

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 9, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate and have had an inadequate response to a single TNF-alpha antagonist. The study will last for approximately six months.

Conditions

  • Rheumatoid Arthritis

Interventions

  • fostamatinibDrug

    fostamatinib 100 mg twice daily

  • fostamatinibDrug

    fostamatinib 100 mg twice daily/150 mg once daily

  • placeboDrug

    Placebo twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients Achieving ACR20 at Week 24, Comparison Between Fostamatinib and PlaceboTime frame: 24 weeks

Locations

135 sites in 16 countries. Site status is shown where the registry gives one.

  • Research Site

    Anniston, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Tuscaloosa, Alabama

  • Research Site

    Mesa, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Hot Springs, Arkansas

  • Research Site

    Glendale, California

  • Research Site

    La Jolla, California

  • Research Site

    Long Beach, California

  • Research Site

    Palo Alto, California

  • Research Site

    Santa Maria, California

  • Research Site

    Torrance, California

  • Research Site

    Tustin, California

  • Research Site

    Upland, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Bridgeport, Connecticut

  • Research Site

    Trumbull, Connecticut

  • Research Site

    Lewes, Delaware

  • Research Site

    Brandon, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Venice, Florida

  • Research Site

    Zephyrhills, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Canton, Georgia

  • Research Site

    Idaho Falls, Idaho

  • Research Site

    Decatur, Illinois

  • Research Site

    Cedar Rapids, Iowa

  • Research Site

    Bowling Green, Kentucky

  • Research Site

    Elizabethtown, Kentucky

  • Research Site

    Crofton, Maryland

  • Research Site

    Fall River, Massachusetts

  • Research Site

    Worcester, Massachusetts

  • Research Site

    Lansing, Michigan

  • Research Site

    Flowood, Mississippi

  • Research Site

    Florissant, Missouri

  • Research Site

    Richmond Heights, Missouri

  • Research Site

    Las Cruces, New Mexico

Showing 40 of 135 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.